

FINAL RESULTS EUPAS28437

Trajectory analyses of adherence patterns in a real-life moderate to severe asthma population

Job FM van Boven, PharmD, PhD^{1,2,3}, Marjaana Koponen, PhD^{1,4,5}, Samanta Lalic, MPharmPrac^{1,6}, Johnson George, PhD^{1,7}, J. Simon Bell, PhD^{1,4,7}, Mark Hew, MD, PhD^{7,8}, Jenni Ilomaki, PhD^{1,7}

1. Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
2. University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Department of Clinical Pharmacy & Pharmacology, Groningen, Netherlands
3. Medication Adherence Expertise Center of the northern Netherlands (MAECON), Groningen, Netherlands
4. Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland
5. School of Pharmacy, University of Eastern Finland, Kuopio, Finland
6. Pharmacy Department, Monash Health, Melbourne, Victoria, Australia
7. School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
8. Allergy, Asthma & Clinical Immunology, The Alfred Hospital, Melbourne, Australia

Corresponding author:

Job FM van Boven, PharmD, PhD

University of Groningen, University Medical Center Groningen,

Groningen Research Institute for Asthma and COPD (GRIAC),

Department of Clinical Pharmacy & Pharmacology, Groningen, Netherlands

Hanzeplein 1, 9700 RB Groningen, The Netherlands

Email: j.f.m.van.boven@rug.nl

Tel: +31503617893

Summary of study results

BACKGROUND: Global Initiative for Asthma step 5 therapies (GINA-5), other than inhaled corticosteroids and long-acting beta agonists in fixed dose combinations (ICS/LABA FDC), often entail more expensive (e.g. monoclonal biologics) or less safe [e.g. maintenance oral corticosteroids (OCS)] treatments. It is therefore important to assess poor inhaler adherence as a possible cause of sub-optimal response to ICS/LABA FDC before additional GINA-5.

OBJECTIVE: To determine rates of, and time to, additional GINA-5 following first-year ICS/LABA FDC use, and their association with inhaler adherence.

METHODS: Patients initiating ICS/LABA FDC between 2013 and 2017 were identified from Australian national dispensing data. Group-based trajectory modelling was used to estimate medication adherence patterns. Multivariable Cox proportional hazards models were used to examine the association between adherence trajectories and GINA-5 addition during 2-year follow-up.

RESULTS: In total, 3062 new ICS/LABA FDC users were identified of whom 120 (3.9%) received additional GINA-5 (OCS:89; LAMA:39; biologics:<3). Mean time to commencing additional GINA-5 was 705.2 (SD 1.7) days. Adherence trajectories were: non-persistent use (20%), seasonal use (8%), poor adherence (58%), and good adherence (13%). Although poor adherence was associated with longer time to additional GINA-5 (adjusted HR: 0.58; 95% CI: 0.35-0.95), over 80% of additional GINA-5 was commenced in poorly-adherent patients. Use of ≥ 2 OCS/antibiotic courses also predicted additional GINA-5.

CONCLUSIONS: Almost one in 20 people with asthma commenced additional GINA-5 after ICS/LABA initiation, most of whom (>80%) were poorly-adherent to inhaled preventers. There is a substantial unmet need for inhaler adherence to be addressed prior to prescribing additional GINA-5.

Reference:

JF van Boven, M Koponen, S Lalic, J George, JS Bell, M Hew, J Ilomaki.

Trajectory analyses of adherence patterns in a real-life moderate to severe asthma population

Journal of Allergy & Clinical Immunology: In Practice 2020; doi:

10.1016/j.jaip.2019.12.002

Available at:

[https://www.jaci-inpractice.org/article/S2213-2198\(19\)31022-0/abstract](https://www.jaci-inpractice.org/article/S2213-2198(19)31022-0/abstract)